What is the reimbursement policy for crizotinib? How much will it cost to pay for reimbursement?
The original drug Crizotinib (Crizotinib) has been approved by the State Food and Drug Administration to be marketed in China. It has been included in the scope of medical insurance reimbursement and is a Class B drug in the medical insurance. The specific reimbursement ratio varies depending on regions and medical insurance policies. It is currently limited to patients with anaplastic lymphoma kinase (ALK) or ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This means that when domestic patients purchase crizotinib, their medical insurance can cover part of the cost, thereby reducing the patient's financial burden.
Crizotinib is currently on the market and can be used for patients with anaplastic lymphoma kinase (ALK)-positive or ROS1-positive locally advanced or metastatic non-small cell lung cancer; as well as patients with ALK-positive anaplastic large cell lymphoma (ALCL) and ALK translocation inflammatory myofibroblastic tumor (IMT). Neuroblastoma is a rare cancer of the peripheral nervous system that occurs almost exclusively in very young children. Crizotinib is a type of targeted drug therapy called a tyrosine kinase inhibitor (TKI) that kills cancer cells by targeting specific areas of genetic changes that cause cancer.

However, even with medical insurance reimbursement, patients still need to pay a portion of their out-of-pocket costs. The amount of out-of-pocket expenses depends on many factors, including drug prices, reimbursement rates, medical insurance policies, and the patient's personal circumstances. The price of crizotinib may vary between versions, drug companies, hospitals and pharmacies. Medical insurance policies in some regions may have higher reimbursement rates for crizotinib, thereby reducing patients' actual payments. The original drugs currently sold in China are available in two specifications: 250mg*60 capsules and 200mg*60 capsules. The price of each box may be more than 10,000 yuan.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)